S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
NASDAQ:SEEL

Seelos Therapeutics Stock Forecast, Price & News

$1.65
-0.08 (-4.62%)
(As of 12/1/2021 04:35 PM ET)
Add
Compare
Today's Range
$1.60
$1.79
50-Day Range
$1.73
$2.58
52-Week Range
$0.90
$6.60
Volume
136,247 shs
Average Volume
5.49 million shs
Market Capitalization
$168.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.68
30 days | 90 days | 365 days | Advanced Chart
Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Seelos Therapeutics logo

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.

Headlines

Why Seelos Therapeutics Stock Is Trading Higher Today
September 27, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SEEL
Employees
10
Year Founded
N/A

Sales & Book Value

Annual Sales
$380 thousand
Book Value
$0.71 per share

Profitability

Net Income
$-19.10 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
97,885,000
Market Cap
$168.94 million
Optionable
Not Optionable

Company Calendar

Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

822nd out of 1,392 stocks

Pharmaceutical Preparations Industry

390th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

Is Seelos Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seelos Therapeutics stock.
View analyst ratings for Seelos Therapeutics
or view top-rated stocks.

How has Seelos Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SEEL stock has increased by 111.5% and is now trading at $1.65.
View which stocks have been most impacted by COVID-19
.

When is Seelos Therapeutics' next earnings date?

Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Seelos Therapeutics
.

What price target have analysts set for SEEL?

5 equities research analysts have issued 12 month target prices for Seelos Therapeutics' shares. Their forecasts range from $8.00 to $14.00. On average, they anticipate Seelos Therapeutics' share price to reach $10.20 in the next twelve months. This suggests a possible upside of 518.2% from the stock's current price.
View analysts' price targets for Seelos Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Seelos Therapeutics' key executives?

Seelos Therapeutics' management team includes the following people:
  • Raj Mehra, Chairman, President & Chief Executive Officer
  • Jessica Kardish, Vice President-Clinical Development & Operations
  • Michael Golembiewski, Chief Financial Officer
  • Lucas Pilipski, Executive Director-Clinical Operations
  • Tim Whitaker, Chief Medical Officer

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.24%), Gendell Jeffrey L (1.82%), Two Sigma Advisers LP (1.73%), Geode Capital Management LLC (1.68%), Millennium Management LLC (1.32%) and Two Sigma Investments LP (0.96%).
View institutional ownership trends for Seelos Therapeutics
.

Which major investors are selling Seelos Therapeutics stock?

SEEL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Millennium Management LLC, Renaissance Technologies LLC, Deutsche Bank AG, Goldman Sachs Group Inc., California State Teachers Retirement System, and New York State Common Retirement Fund.
View insider buying and selling activity for Seelos Therapeutics
or view top insider-selling stocks.

Which major investors are buying Seelos Therapeutics stock?

SEEL stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Two Sigma Advisers LP, Vontobel Holding Ltd., Geode Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., Penserra Capital Management LLC, Gendell Jeffrey L, and Franklin Resources Inc..
View insider buying and selling activity for Seelos Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $1.65.

How much money does Seelos Therapeutics make?

Seelos Therapeutics has a market capitalization of $168.94 million and generates $380 thousand in revenue each year. The company earns $-19.10 million in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Seelos Therapeutics have?

Seelos Therapeutics employs 10 workers across the globe.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is www.seelostherapeutics.com.

Where are Seelos Therapeutics' headquarters?

Seelos Therapeutics is headquartered at 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at (646) 293-2100, via email at [email protected], or via fax at 858-436-8155.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.